Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-16-006052
Filing Date
2016-05-17
Accepted
2016-05-17 16:06:41
Documents
44
Period of Report
2016-05-31

Document Format Files

Seq Description Document Type Size
1 6-K sbbp-20160531x6k.htm 6-K 940589
  Complete submission text file 0001558370-16-006052.txt   3532321

Data Files

Seq Description Document Type Size
2 EX-101.INS sbbp-20160531.xml EX-101.INS 663027
3 EX-101.SCH sbbp-20160531.xsd EX-101.SCH 31819
4 EX-101.CAL sbbp-20160531_cal.xml EX-101.CAL 32669
5 EX-101.DEF sbbp-20160531_def.xml EX-101.DEF 102937
6 EX-101.LAB sbbp-20160531_lab.xml EX-101.LAB 308710
7 EX-101.PRE sbbp-20160531_pre.xml EX-101.PRE 206828
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

EIN.: 981130690 | State of Incorp.: L2
Type: 6-K | Act: 34 | File No.: 001-37569 | Film No.: 161657576
SIC: 2834 Pharmaceutical Preparations